Discover
BBOT
BridgeBio Oncology Therapeutics Inc.
9.06
2 x 9.07
8 x 9.09
bid
ask
-
0.17
1.84%
1 @ 04:00 PM
9.06 +0.00 (0.00%)
| Ytd | -27.64% | |
| 1y | -9.31% |
8.85
day range
9.25
7.12
52 week range
13.73
| Open | 9.25 | Prev Close | 9.23 | Low | 8.85 | High | 9.25 | Mkt Cap | 725.77M |
| Vol | 227.29K | Avg Vol | 407.85K | EPS | -2.01 | P/E | -4.51 | Forward P/E | N/A |
| Beta | 0.36 | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.28 | 200-d Avg | 10.04 | 1yr Est | 24.20 |
BBOT News
globenewswire.com
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
globenewswire.com
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing